Drug Profile
LIT 976
Alternative Names: LIT976Latest Information Update: 18 Dec 2021
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Antineoplastics; Radiopharmaceutical diagnostics; Small molecules; Taxanes
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 07 Mar 2002 Phase-II clinical trials in Cancer in USA (unspecified route)
- 04 Jul 2001 Preclinical development for Cancer in USA (Unknown route)